Navigation Links
HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy

According to researchers, Breast Cancer Patients with HER-2 Positive tumor who do not respond well to Herceptin alone could benefit// with a combination of drug Herceptin and one or more P13K-inhibiting agents.

The research team at the University of Texas M.D. Anderson Cancer Center in Houston is due to conduct anther trial, after having successfully tested it on mice. The second stage of the trial, will involve severe cancer cases where the disease has advanced in spite of Herceptin Treatment in Her2 positive patients.

Study author Dr. Dihua Yu, a professor in the department of surgical oncology said 'More than half of patients with HER2-positive tumors don't respond to Herceptin as a single agent, and our research has shown us why that is and what might be done to help these patients. If this drug cocktail shows benefit, we hope to be able to identify those patients who won't respond to Herceptin before they start the treatment, and offer them a new and beneficial drug combination. Patients who don't respond to Herceptin have worrisome outcomes, so we hope this strategy will help them.'

There is ample indication, supported by successful outcomes of previous research, which has provided the impetus to a combination treatment for aggressive breast cancers.


'"/>




Page: 1

Related medicine news :

1. When Her Lot is maligned by HER-2, Staying Abreast is Imperative
2. The Positive Effects Of A Healthy Lifestyle
3. The Positive Effects Of A Healthy Lifestyle
4. Positive Thinking
5. Ruling On Non Disclosure Of HIV Positive Status Is Not Ethical
6. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
7. HIV Positive People Touching 60,000 In UK
8. Russian Miss HIV Positive Says Victims Are Treated Like Prostitutes
9. HIV Positive Men in Singapore Exposed
10. Positive Emotions lead To Life Longevity
11. New Fund Launched To Help HIV Positive Women
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: